To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Single-Dose IA ropivacaine reduces pain up to 8 hours post arthroscopic knee surgery

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
October 2015

Single-Dose IA ropivacaine reduces pain up to 8 hours post arthroscopic knee surgery

Vol: 4| Issue: 10| Number:51| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Single-dose intra-articular ropivacaine after arthroscopic knee surgery decreases post-operative pain without increasing side effects: a systematic review and meta-analysis

Knee Surg Sports Traumatol Arthrosc. 2016 May;24(5):1651-9

Contributing Authors:
Y Zhou TB Yang J Wei C Zeng H Li T Yang GH Lei

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

8 randomized controlled trials (RCTs), with 567 patients who underwent arthroscopic knee surgery and used either single-dose intra-articular (IA) ropivacaine or a postoperative analgesic for pain management were included in the study. The purpose of this study was to determine the efficacy of intra-articular ropivacaine in providing post-surgery pain management while examining the incidence of sid...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue